COVID-19 RESPONSE

Lifespan continued its coordinated COVID-19 response through initiatives such as vaccine clinics, community programs, and innovative research.

• The Miriam Hospital launched a new clinic led by Jennie Johnson,

MD, to treat patients with long COVID, a condition characterized by symptoms that persist for four weeks or more after an initial COVID-19 infection has run its course.

Jennie Johnson, MD Clinical Trial for Convalescent Plasma Treatment for COVID-19, Rhode Island Hospital

• Lifespan’s employee vaccination program began on December 14, 2020, when it became the first healthcare system in New England to start distribution. By October 1, 2021, Lifespan had achieved a 98-percent employee vaccination rate.

• Hasbro Children’s Hospital offered monoclonal antibody treatments to pediatric patients who contracted COVID-19.

• Hasbro Children’s Hospital joined the $470 million Researching COVID to Enhance Recovery (RECOVER)

Initiative to study the impact of Long COVID in infants, children, and adolescents. The nationwide study includes such partners as NYU Langone Health, Virginia Commonwealth University, and Northeastern University. • The Miriam Hospital was named a clinical trial site for the National Institutes of Health ACTIV-2 study, testing potential breakthrough treatments for COVID-19 outpatients. • Through a series of multicenter trials, Rhode Island Hospital teamed up with researchers at Johns Hopkins University to test the efficacy of convalescent plasma therapy as a potential early treatment for COVID-19.

thank you to lifespan’s employees